ERBB2 and breast carcinoma: This study firstly found that reversible senescence contributed to LAP(lapatinib) resistance in HER2+ breast cancer and identified ecto‐5′‐nucleotidase (NT5E) as a marker of reversible senescence in HER2+ breast cancer.